about
Peptide microarrays for the detection of molecular interactions in cellular signal transductionKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated PatientsThe IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 mont[New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view].Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur MultidisciplinairGemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.[Microangiopathic hemolytic anemia associated with uterine sarcoma: report of a case. Review of the literature].Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic studyPhase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer.[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon CancerGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].Effect of skin hydration on the dynamics of fingertip gripping contact.[Nab-paclitaxel].An overview of adjuvant systemic chemotherapy for colon cancer.Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III TrialSurvival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use programA randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
P50
Q24300136-E396E97B-9E46-42C2-BE4A-B6C151AD3EE2Q27851422-A30A32E5-120C-434A-9732-7BF37CEC9211Q28547481-8BBAC710-2637-4F69-9E05-EE9F67B27B95Q28681140-36376F5C-8E39-4CAE-8046-D2EDEE274B0FQ30249322-C0F5463B-67BB-410B-916F-0C06DE2C94A0Q30301332-A1EC658F-9F53-42BF-BB63-4E821CE5AD14Q30315675-0E7D25A5-8256-432E-BB52-BAD4CCAFCCBDQ30317428-B170C56F-F019-4617-B2FA-2D0EC429E4C0Q30585579-AAF675C8-DB44-4618-9B19-AAD9E6BA0EA7Q31155033-03660751-138D-4211-AB95-BCB1FB9A42AFQ33337184-34AEDFE3-7ABC-41CC-AE73-4B4757DE6532Q33341477-DA24BB41-1C07-4218-892E-275CFCA96139Q33345474-DC677293-2EC0-47BA-94FB-06739B408ECDQ33362191-EC844E4F-7914-4AD1-BFEF-38F730945D94Q33364579-0FE54C81-9246-4ED9-8A5F-FFE53E2C0976Q33372916-EC4B36DA-8E02-4105-A8FF-BE6A66C017DCQ33378806-938FB17E-9068-4A04-81E3-98CA1613E22AQ33383423-B3D12848-43E3-47C5-BAD2-B4E32C80DD43Q33417895-EC1D5C57-B1A3-450C-B262-1F142D2BECA4Q33440884-BA4D2BBC-9202-4227-BED5-EBA94B9A9EE7Q33496740-5BBED7F2-3A73-4E25-A628-99866E5B6535Q33497973-997F76FE-F982-43B8-A69A-893E20F4E886Q33682949-7DBD8A53-F236-4F1A-A6FE-82D7DC765B5CQ33781269-0D984F63-5AE1-4008-B538-9BCABBA01D6FQ34106002-F0B26FA9-246C-486D-B08D-C0FAB944A622Q34472453-C9ACF58E-6798-47E5-974E-0895134E545FQ34557866-18063FEC-05BF-431D-A6CD-6BA9E25196B5Q34624122-2D1DB7FA-CEA4-4087-A3F3-D2640787A2C1Q34645599-424988E8-522E-4B7C-AAD6-8070CFD9A053Q34654266-6E30258B-5506-439B-84D8-9890C111D06CQ34658519-8CCF3807-040C-43A5-9749-E3F5589CC8EEQ34665199-47C2E392-51AA-4B2C-8F3A-9D065B345384Q34746001-065B7DFF-1952-407A-BF3F-B4313802FEEFQ35225176-2531D8E4-F101-4B15-A109-913AFE9C0E89Q35640791-AC459552-ECF6-42AB-A7AB-FE207CAD57AFQ35814568-1D86FDEB-9A4C-43D2-B351-A5BB80D23DA8Q35917852-921B2CE5-8080-4BDC-B1EF-4631D24F7BFCQ36054226-B6A8D9F8-B546-41FD-B5B4-8427A49E53C3Q36070573-0A6EDE2F-9054-40E6-B430-4953A7C8C90EQ36131174-1DE3E7E0-133F-4C0C-8E36-B5FA18402446
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
T André
@ast
T André
@en
T André
@es
T André
@nl
T André
@sl
type
label
T André
@ast
T André
@en
T André
@es
T André
@nl
T André
@sl
prefLabel
T André
@ast
T André
@en
T André
@es
T André
@nl
T André
@sl
P106
P31
P496
0000-0002-5103-7095